1. Scrip
  2. >>R&D

Ichnos CEO On The ‘ASH Of Bispecifics’, Progress With Trispecific

 
• By Anju Ghangurde

Ichnos’ CEO Dr Cyril Konto highlights promising early data presented at ASH for the firm’s trispecific antibody in multiple myeloma versus teclistamab and alnuctamab. He also outlines why the US-based spin out of Glenmark isn’t considering the special purpose acquisition company alternative to the conventional IPO.  

Ichnos progresses myeloma assets • Source: Shutterstock

The recently concluded American Society of Hematology (ASH) annual meeting could well be “re-baptized as the ASH of bispecifics”, said Ichnos Sciences, Inc. president and CEO, Dr Cyril Konto, highlighting the potential of the growing class of antibody-based immunotherapies.

In an interview with Scrip, Konto, who was at the 64th ASH meeting in New Orleans earlier this month, outlined ‘tremendous progress’ made in the area, referring not just to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Executives On The Move: Innate Pharma And Alloy Therapeutics Get New CEOs

Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.